International urticaria guidance recommends a standard dose of a second-generation, non-sedating antihistamine first, and if control is inadequate after two to four weeks, increasing the same drug up to four times the licensed dose before adding omalizumab or other agents. Many patients labelled as antihistamine failures have never been updosed.
Use a validated score such as the weekly urticaria activity score (UAS7) to decide whether control is adequate, rather than an impression at the clinic visit. Sedating first-generation antihistamines are not recommended for long-term use.
- Start one second-generation antihistamine at standard dose, taken regularly rather than as needed.
- If symptoms persist after two to four weeks, increase the same drug up to fourfold before adding another agent.
- Record UAS7 at each visit so the decision to escalate rests on a number.
- Avoid long-term first-generation antihistamines, which sedate and impair performance.
- Explain that updosing is off-licence but guideline-supported and generally well tolerated.
Why it matters
Updosing settles many patients and spares a costly biologic for those who genuinely need it.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free